Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQ: MRVI · Real-Time Price · USD
4.850
+0.910 (23.10%)
At close: May 8, 2026, 4:00 PM EDT
4.720
-0.130 (-2.68%)
After-hours: May 8, 2026, 7:58 PM EDT
MRVI Stock Forecast
Stock Price Forecast
The 4 analysts that cover MRVI stock have a consensus rating of "Buy" and an average price target of $4.38, which forecasts a -9.69% decrease in the stock price over the next year. The lowest target is $2.00 and the highest is $5.50.
Price Target: $4.38 (-9.69%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for MRVI stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 3 | 3 | 3 | 3 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $4.5 → $5.5 | Buy | Maintains | $4.5 → $5.5 | +13.40% | May 8, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $4 → $4.5 | Buy | Maintains | $4 → $4.5 | -7.22% | Dec 15, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $10 → $5 | Strong Buy | Maintains | $10 → $5 | +3.09% | Aug 12, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $7 → $5 | Buy | Maintains | $7 → $5 | +3.09% | Aug 12, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +106.19% | May 13, 2025 |
Financial Forecast
Revenue This Year
209.03M
from 185.74M
Increased by 12.54%
Revenue Next Year
225.48M
from 209.03M
Increased by 7.87%
EPS This Year
-0.19
from -0.91
EPS Next Year
-0.16
from -0.19
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 218.7M | 239.4M | ||||||
| Avg | 209.0M | 225.5M | ||||||
| Low | 197.3M | 212.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 17.8% | 14.5% | ||||||
| Avg | 12.5% | 7.9% | ||||||
| Low | 6.2% | 1.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.13 | -0.09 | |||
| Avg | -0.19 | -0.16 | |||
| Low | -0.26 | -0.25 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.